Altered myocardial fuel selection likely underlies cardiac disease risk in diabetes, 3 affecting oxygen demand and myocardial metabolic flexibility. We investigated 4 myocardial fuel selection and metabolic flexibility in human Type 2 Diabetes 5 (T2DM), using positron emission tomography to measure rates of myocardial fatty 6 acid oxidation (16-18 F-fluoro-4-thia-palmitate, FTP), and myocardial perfusion and 7 total oxidation ( 11 C-acetate). Participants underwent paired studies under fasting 8 conditions, comparing 3-hour insulin+glucose euglycemic clamp conditions (120 9 mU/m 2 /min) to 3-hour saline infusion. Lean controls (n=10) were compared with 10 glycemically controlled volunteers with T2DM (n=8). Insulin augmented heart rate, 11 blood pressure and stroke index in both groups (all p<0.01), and significantly 12 increased myocardial oxygen consumption (p=0.04) and perfusion (p=0.01) in both 13 groups. Insulin suppressed available non-esterified fatty acids (p<0.0001), but fatty 14 acid concentrations were higher in T2DM under both conditions (p<0.001). Insulin-15 induced suppression of fatty acid oxidation was seen in both groups (p<0.0001). 16
Introduction 31
Alterations in metabolic substrate uptake and metabolism are part of the phenotype 32 that defines Type 2 diabetes mellitus (T2DM) (3, 4, 33, 39, 74) . The phenomenon of 33 'metabolic flexibility' is the capacity of an organism, a tissue bed, or a cell system to 34 switch readily among fuel types. Impaired metabolic flexibility is another 35 phenotypic feature of T2DM (33, 66) . Impaired metabolic flexibility has been 36 demonstrated in skeletal muscle in human diabetes (32, 66) . This whole-body effect 37 likely arises due to effects of impaired insulin-stimulated glucose uptake, together 38 with abnormalities in availability, uptake and metabolism of fatty acid fuels (33, 66, 39 75) . 40
The myocardium is also affected by T2DM. The fuel needs of the heart are 41 dramatically different than those of skeletal muscle, supporting continuous work 42 even under resting conditions. Abnormalities in myocardial fuel selection in animal 43 models of diabetes have been described (42, 54, 75) , including impairments in 44 insulin-stimulated glucose uptake and impaired suppression of myocardial fatty 45 acid uptake by insulin. The capacity for flexible selection among fuel sources has 46 implications for ischemia tolerance, as the oxygen requirements for metabolizing 47 fatty acids are higher than those for carbohydrates (43) , and may contribute to 48 efficiency of supplying fuel for contractile function more generally. Most studies to 49 date that evaluated metabolic flexibility of the diabetic heart have studied the 50 insulin deficient state, i.e. models of Type 1 diabetes (5, 42, 54) . Very little data exist 51 exploring effects of Type 2 diabetes on myocardial fuel selection, and data is 52 particularly lacking in human T2DM (75). Here we describe studies in non-obese 53 non-diabetic control and obese Type 2 diabetic humans, using positron emission 54 tomography (PET) to quantify the effect of insulin to drive myocardial fuel selection 55 away from fatty acids. We present evidence for metabolic inflexibility in the diabetic 56 heart in Type 2 diabetes mellitus, owing to diabetes-related abnormalities in fatty 57 acid uptake and in fatty acid availability. 58 59 7 ventricle cavity, concurrently identified, served as an arterial blood pool from which 150 the input function was derived. Following acetate infusion, serial timed peripheral 151 blood samples were taken (at minutes 0, 3,6,10,15,20,25 and 30) and immediately 152 analyzed for circulating concentrations of labeled CO 2 and later used as a correction 153 for the image-derived input function (11, 53) . Similarly, timed samples were taken 154 at these same intervals following FTP infusion and assayed for total and FTP-155 specific radioactivity in order to determine metabolite correction curves for the 156 input function. 157
Compartmental modeling using a 2-compartment model was applied to the 158 metabolite-corrected acetate data to derive separate terms for influx and efflux 159 kinetics. Myocardial blood flow was measured directly from the influx kinetic 160 parameter k1 (31, 47). Myocardial oxygen consumption was derived from the efflux 161 parameter k2 using k2 = 0.0071 + 0.0074(MVO2) (67), as we have done previously 162 (47). For FTP kinetics we applied Patlak analysis to derive uptake kinetics using 163 metabolite-corrected input functions (55). In exploratory analyses we applied a 164 variety of 2-and 3-compartment models, but owing to the monotonic uptake of FTP 165 in many individual datasets were unable to derive kinetic constants beyond simple 166 uptake kinetics; therefore data are only presented for Patlak-derived results. 167
The slope of the Patlak plot (K i ) for FTP represents the net rate at which the 168 radiotracer is trapped, incorporating rates of fatty acid uptake and efflux prior to 169 metabolic trapping. Multiplying K i values by ambient non-esterified fatty acid 170 concentrations at the time of fatty acid imaging provided net rates of fatty acid 171 oxidation (FAO=K i *NEFA/LC), where a lumped constant (LC) value of 2.10 was 172 applied to account for the difference of FTP kinetics to natural fatty acid kinetics as 173 based on studies in isolated rat hearts under normoxic conditions (19) . 174
Impedance Cardiography: Systemic hemodynamic parameters were measured in 175 order to assess cardiac work during the measurements of metabolic rates. 176
Conventional automated cuff-derived blood pressures were measured concurrently 177 with impedance cardiography (BioZ.com, CardioDynamics, San Diego CA). 178
Impedance cardiography provides a non-invasive measure of cardiac output and 179 8 other systemic hemodynamic parameters, deriving parameters from cyclical 180 fluctuations in the electrical resistance (impedance) of the with the cardiac cycle. 181
The waveform directly reflects stroke volume, allowing derivation of cardiac output 182 and (together with blood pressure measures) cardiac work (17, 27) . The use of this 183 system allowed repeated measurements to be made noninvasively during the 184 course of the PET imaging with the subject positioned in the scanner. Steady state 185 measurements were taken twice, at 120 minutes (steady state, start of PET 186 scanning) and at the end of the scan sequence, and the mean of these readings was 187 taken to reflect cardiac status at the time of PET imaging. 188
Analyte Measurement The concentrations of glucose in arterialized blood samples 189 was measured by a glucose oxidase method (Model 2300 Yellow Springs 190 Instruments, Yellow Springs, OH). Blood for determination of other analytes was 191 frozen at −80°C. Insulin determinations were made using a dual-site 192 radioimmunoassay (Millipore, Billerica, MA). Non-esterified fatty acid 193 measurements were performed using a colorimetric assay (Wako Diagnostics, 194 Richmond VA). Cholesterol and triglyceride measures were made using standard 195 methodologies through our local hospital's clinical laboratory 196
Statistical Approach 197
Descriptive statistics were presented as mean ± standard deviation; other results 198 were presented as mean±SEM. Normality of distribution of variables was assessed 199 graphically, and by statistical testing using a Kolmogrov Smirnov test; no variables 200 required transformation in order to apply parametric testing. Baseline 201 characteristics were compared between groups using unpaired t-tests. 202
The overall comparison of interest is in the set of measurements made at the time of 203 PET imaging, comparing the two study groups. We used a mixed model approach, 204 comparing effects of the insulin/glucose clamp versus saline on parameters 205 measured at the time of PET imaging across groups. For parameters where pre-PET 206 values were measured (e.g. baseline and steady state values on each study day), 207 these were also incorporated into the analyses. Analyses were also performed 208 comparing the two treatment groups under steady state insulin conditions, in order 209 9 to highlight differences in the achieved metabolic or hemodynamic effects. 210
Regression analyses were used to evaluate the determinants of myocardial fuel 211 consumption, efficiency, and blood flow under these treatment conditions. 212
Statistical analyses were performed using SPSS version 23 (IBM, Chicago IL). 213
Statistical power for this study was based on the PET endpoints of blood flow, 214 oxidation rate, and fatty acid utilization. For the acetate-derived measures the 215 population variability observed by us and by others is on the order of 15% 216 (coefficient of variation), i.e. 1SD ~0.15 of mean values (23, 36) . At the time of this 217 study no estimate of variability for the FTP imaging in humans was available; we 218 assumed it was similar to that of the acetate parameters. Based on this estimate, we 219 calculated that 9 participants per group would be sufficient to demonstrate 220 between-group differences on the order of 1SD at 83% power. To allow for dropouts 221 and incomplete data, we planned to recruit 10 subjects per group. 222 223 224
Results

225
Characteristics of the participants are described in 6.3±0.3 control day, 7.0±0.5 clamp day). These values were significantly higher than 237 those of the lean controls (p<0.0001) but not different within diabetic subjects 238 across the two study days (p=0.08). On the control day, no study-imposed change in 239 these values was undertaken, but on the clamp day we targeted a steady-state 240 glucose value of 5 mmol/L. 241
The non-esterified fatty acid (NEFA) concentrations were higher in the diabetic 242 participants (fasting saline control day p=0.46, insulin-glucose clamp steady state 243 p=0.001) and were less completely suppressed by the high-dose insulin infusion 244 than was achieved in the lean control subjects ( Table 1) Under control and insulin treated conditions, lean subjects had numerically but not 255 statistically lower insulin concentrations than the diabetic subjects ( Table 1) these insulin-stimulated, low NEFA conditions, net fatty acid uptake (Patlak Ki) was 284 significantly increased in both groups (Figure 3) , numerically but not significantly 285 higher in T2DM. Together these factors produced a persisting significantly elevated 286 fatty acid oxidation rate in T2DM even under high-dose insulin exposure. Although 287 the between-group differences in fatty acid oxidation rates did not achieve 288 significance when comparing all values (p=0.07), the rates were significantly 289 different under steady state insulin clamp conditions (FAO at steady state 0.13±0.14 290 µmol/100g/min lean vs 0.49±0.15 T2DM, p=0.005). 291
There were modest between-group differences in the measures of cardiac work, not 292 achieving statistical significance (Table 2, Figure 2) ; there were no group 293 differences in the effects of insulin on cardiac work. Adjusting FAO for cardiac work 294 did not materially change the overall result regardless of whether the selected 295 measure of work was MVO 2 (Figure 3) , CI or LCWI (not shown), with higher work-296
adjusted FAO values in T2DM than controls. 297
We explored a number of potential contributors to the baseline and insulin-induced 298 changes in fatty acid oxidation, including age, sex, race/ethnicity, baseline fatty acid 299 and glucose concentrations, insulin-stimulated glucose disposal rate (i.e. insulin 300 resistance), myocardial oxygen consumption and myocardial blood flow. Including 301 these parameters in a sequence of multivariable regression analyses (not shown), 302 the only significant independent determinants of fatty acid oxidation were NEFA 303 concentrations and glucose disposal rate (both p<0.001). These parameters exerted 304 effects in addition to the effect of insulin in the analyses of insulin-induced change in 305 FAO (not shown). 306
One expected effect of changes in fuel substrate is a change in myocardial efficiency, 307
i.e. work done per unit oxygen consumed. We therefore analyzed measures of 308 cardiac work relative to the insulin-induced shift in fuel utilization. conditions. Insulin treatment resulted in reductions in fatty oxidation in both 329 control and T2DM participants, but the achieved rates of myocardial fatty oxidation 330 remained elevated in T2DM compared to controls. This arose due to combined 331 effects of higher rates of FTP trapping (K i ) and less effective insulin-induced 332 suppressions of fatty acid availability in T2DM. We also observed impaired 333 myocardial work efficiency in type 2 diabetes. 334
Metabolic flexibility in the heart. The concept of metabolic inflexibility was 335 originally proposed as a phenomenon of impaired fuel switching in skeletal muscle 336 in obesity and diabetes, but applies equally to fuel selection in the heart. Given the 337 energy needs of the heart and an existing preference for fatty acid fuel sources, it is 338 not obvious a priori that obesity-related differences in fatty acid availability and 339 uptake would be detrimental to the myocardium. Nevertheless, many prior reports 340 have linked obesity and insulin resistance with increased myocardial fatty acid 341 uptake and utilization (6, 8, 10, 13, 26, 37, 38, 48, 49, (56) (57) (58) 62) . Further, it is 342 apparent from a number of experimental studies limiting or augmenting fatty acid 343 uptake that the increased fatty acid uptake can contribute to impairments in 344 myocardial function (2, 22, 25, 28, 34, 44, 48, 50, 51, 59, 73) . 345
Our data implicate abnormalities in myocardial fatty acid transport in addition to 346 failure to suppress adipose fatty acid release in the excess fatty acid uptake and 347 oxidation in type 2 diabetes. Diabetes-related differences were observed in the fatty 348 acid uptake kinetic as well as in the availability of fatty acid substrate, under control 349 and insulin-stimulated conditions, and the net difference between groups results 350 from combined effects of both of these phenomena. These data are consistent with 351 observations of increased myocardial fatty acid uptake in animal models of insulin 352 resistance (12-14, 16, 37, 50, 54) , and in obesity/insulin resistance in humans (40, 353 49, 56, 57) , here extended into observations in human Type 2 diabetes. In humans, 354
PPARgamma agonists and weight loss can improve the abnormally increased fatty 355 acid uptake (29, 41, 72) , suggesting this phenomenon is subject to remodeling and 356 not a fixed feature of the diabetic state. Experimental data supports diabetes-related 357 abnormalities in myocardial content and function of CD36 and FATP, the major 358 sarcolemmal fatty acid transport proteins (1, 9, 15, 24, 37, 46, 64, 73) . Consistent 359 with experimental evidence in animal models (1, 9, 22, 45, 73) , the importance of 360 CD36 for human myocardial fatty acid uptake was recently demonstrated in a family 361 recognized to have CD36 deficiency (30). Lipoprotein lipase, functioning in 362 adipocytes or in vasculature more proximal to the myocardium, has also been 363 implicated as a contributor to the detrimental phenotype of elevated fatty acid 364 uptake (35). Overall the presence of combined defects in fatty acid uptake and 365 availability presents an opportunity and a need to address both factors concurrently 366 in order to rescue the obese/diabetic heart from the effects of increased fatty acid 367 uptake. 368
Myocardial efficiency: We observed reduced myocardial work efficiency in type 2 369 diabetes compared to lean controls. This observation is in line with data from 370 animal models (50, 61) and from obese humans (49, 56, 58), and augments the 371 sparse human data evaluating this feature of myocardial function in human 372
diabetes. 373
We observed a further reduction in work efficiency (i.e. more oxygen consumed per 374 unit work) with the euglycemic hyperinsulinemic clamp. This reduction was seen in 375 both study groups, while maintaining the between-group difference noted under 376 baseline conditions. This was concurrent with an observed reduction in fatty acid 377 oxidation, and with an insulin-induced increase in cardiac work. This result is 378 paradoxical since the shift from fat oxidation (requiring 0.24 mole O 2 per mole ATP 379 generated) to glucose (0.16 mole O 2 per mole ATP generated) (43) was expected to 380 produce an improvement in metabolic efficiency. Direct changes in cardiac work 381 have been shown to improve efficiency (dilated cardiomyopathy treated with 382 vasodilator) (7), reduce efficiency (healthy humans subjected to right ventricular 383 pacing tachycardia) (71), and leave efficiency unchanged (healthy humans subjected 384 Our study has a number of limitations. In our assessment of metabolic flexibility we 402 used 2 tracers to evaluate total oxidative metabolism ( 11 C-acetate) and rates of fatty 403 acid oxidation ( 18 F-FTP), but did not include a 3 rd tracer to allow measurement of 404 carbohydrate metabolism. We therefore do not have concurrent direct evidence of 405 fuel shifts toward carbohydrate use, but have inferred this from the large measured 406 reductions in fatty acid uptake and utilization and from the known effects of insulin 407 to drive glucose uptake and utilization in the heart. We did not include a group of 408 obese non-diabetic individuals, to evaluate whether the observed effects were 409 specific to the diabetic state. We studied a comparatively small number of 410 participants, and therefore were not powered to demonstrate potentially important 411 but small differences between groups. Nevertheless we observed important and 412 highly statistically significant effects of parameters related to our main study design 413 questions. We had an unbalanced sex distribution between groups, which was 414 potentially important given that others have demonstrated sex-specific differences 415 in myocardial fuel selection (57). Our population had too few female participants to 416 allow meaningful post-hoc analyses by sex, and in particular female participants 417 were uniquely present in the T2D group which could have contributed to the 418 observed between-group differences; this will require further study with sufficient 419 sample sizes in both sexes. The specialized fatty acid tracer FTP produced a more 420 direct measure of fatty acid oxidation rate than is provided by traditional 11 C-421 palmitate tracer methodology, but conversely did not allow us to derive rates of 422 transport, esterification, storage or reverse transport out of the mitochondrion from 423 compartmental modeling such as can be done with unmodified palmitate tracers . 424
The FTP-derived rate of fatty acid oxidation is, however, more directly and simply 425 
